<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900584</url>
  </required_header>
  <id_info>
    <org_study_id>2019ER630301</org_study_id>
    <nct_id>NCT04900584</nct_id>
  </id_info>
  <brief_title>Optimize Heart Failure Care During TRANSitional Period in Patients With Acute Heart Failure.</brief_title>
  <acronym>TRANS-HF</acronym>
  <official_title>A Prospective Randomized Multicenter Controlled Study to Optimize Heart Failure Care During TRANSitional Period in Patients With Acute Heart Failure With Reduced Ejection Fraction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wonju Severance Christian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The period of about a month after the discharge of acute heart failure patients is defined as&#xD;
      a transition time. During this period, the patient has a high mortality rate and a&#xD;
      readmission rate because the patient is not stabilized. In the United States and Europe, the&#xD;
      readmission rate is more than 25% within 30 days, and the mortality rate within 30 days after&#xD;
      discharge is three times that of patients with chronic heart failure.&#xD;
&#xD;
      The TRANS-HF is a prospective, randomized, multi-center, controlled study, which enrolls&#xD;
      patients with acute heart failure with reduced ejection fraction.&#xD;
&#xD;
      The objective of TRANS-HF is to improve GAI at six months through three interventions:&#xD;
      pre-discharge checklist, heart failure education, and telephone monitoring before the first&#xD;
      outpatient visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Guideline adherence indicator at 6months</measure>
    <time_frame>6months</time_frame>
    <description>the point of Guideline adherence indicator. Definition of GAI strata : Level of guideline-adherent treatment will be measured by guideline adherence indicator (GAI) such as 0/3, 1/3, 2/3, and 3/3. This GAI data will be obtained once after all prescription data has been collected. It will include whether or not prescribed medication of ≥50% of target dose : 0 points for non-prescription in the absence of contra-indications, 0.5 points for use of &lt;50% of target dosage (&lt;100% of target dose for MRA as the majority of patients were treated with ≥50% of target dose of MRA) or 1 point for use in ≥50% of target dosage (target dose for MRA). Non-administration of recommended drugs due to specific contraindications or intolerance will be scored as adherence to guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Guideline adherence indicator at discharge</measure>
    <time_frame>0 day (at discharge)</time_frame>
    <description>the point of Guideline adherence indicator. Definition of GAI strata : Level of guideline-adherent treatment will be measured by guideline adherence indicator (GAI) such as 0/3, 1/3, 2/3, and 3/3. This GAI data will be obtained once after all prescription data has been collected. It will include whether or not prescribed medication of ≥50% of target dose : 0 points for non-prescription in the absence of contra-indications, 0.5 points for use of &lt;50% of target dosage (&lt;100% of target dose for MRA as the majority of patients were treated with ≥50% of target dose of MRA) or 1 point for use in ≥50% of target dosage (target dose for MRA). Non-administration of recommended drugs due to specific contraindications or intolerance will be scored as adherence to guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Guideline adherence indicator at 1month</measure>
    <time_frame>1month after discharge</time_frame>
    <description>the point of Guideline adherence indicator. Definition of GAI strata : Level of guideline-adherent treatment will be measured by guideline adherence indicator (GAI) such as 0/3, 1/3, 2/3, and 3/3. This GAI data will be obtained once after all prescription data has been collected. It will include whether or not prescribed medication of ≥50% of target dose : 0 points for non-prescription in the absence of contra-indications, 0.5 points for use of &lt;50% of target dosage (&lt;100% of target dose for MRA as the majority of patients were treated with ≥50% of target dose of MRA) or 1 point for use in ≥50% of target dosage (target dose for MRA). Non-administration of recommended drugs due to specific contraindications or intolerance will be scored as adherence to guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KCCQ(The Kansas City Cardiomyopathy Questionnaire) at discharge</measure>
    <time_frame>0 day (at discharge)</time_frame>
    <description>the score of the Kansas City Cardiomyopathy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KCCQ(The Kansas City Cardiomyopathy Questionnaire) at 6 months</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>the score of the Kansas City Cardiomyopathy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D(The EuroQoL five-dimensional instrument) at discharge</measure>
    <time_frame>0 day (at discharge)</time_frame>
    <description>the score of the EuroQoL five-dimensional instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D(The EuroQoL five-dimensional instrument) at 6 months</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>the score of The EuroQoL five-dimensional instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>up to 6 months</time_frame>
    <description>incidence rate (%) of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure rehospitalization</measure>
    <time_frame>up to 6 months</time_frame>
    <description>incidence rate (%) of the first rehospitalization due to heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>up to 6 months</time_frame>
    <description>incidence rate (%) of death due to heart failure, arrhythmia and cerebrovascular event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular rehospitalization</measure>
    <time_frame>up to 6 months</time_frame>
    <description>incidence rate (%) of the first rehospitalization due to heart failure, arrhythmia, and cerebrovascular event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite end-point</measure>
    <time_frame>up to 6 months</time_frame>
    <description>incidence rate (%) of all-cause death and the first rehospitalization rehospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">998</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group is managed by applying all three types of intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-Intervention group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-intervention group is managed by conventional heart failure treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Checklist</intervention_name>
    <description>Checklist of guideline-based treatment before discharge</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Education</intervention_name>
    <description>Heart failure education before discharge</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone monitoring</intervention_name>
    <description>Telephone monitoring after discharge</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All consecutive hospitalized adult heart failure patients who fulfill one of 1-3 and&#xD;
        satisfy 4-5 simultaneous&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptoms of heart failure&#xD;
&#xD;
          2. Signs of heart failure&#xD;
&#xD;
          3. Lung congestion in Chest-X-ray&#xD;
&#xD;
          4. Objective finding of structural and/or functional disorder of the heart or elevated&#xD;
             natriuretic peptide levels&#xD;
&#xD;
          5. Left ventricular ejection fraction less than 40%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 19 years old&#xD;
&#xD;
          2. Patients who do no consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-Su Yoo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonju Severance Christian Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byung-Su Yoo, MD, PhD</last_name>
    <phone>82337410917</phone>
    <email>yubs@yonsei.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-Woo Son, MD</last_name>
    <phone>82337410918</phone>
    <email>sonjwoo@yonsei.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital,</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Su Yoo, MD, PhD</last_name>
      <phone>82337410917</phone>
      <email>yubs@yonsei.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jung-Woo Son, MD</last_name>
      <phone>82337410918</phone>
      <email>sonjwoo@yonsei.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

